AbbVie to present Phase 2 APEX Part B data on zumilokibart at EADV 2026
AbbVie flagged late-breaking Phase 2 findings for investigational zumilokibart in moderate-to-severe atopic dermatitis, plus late-breaking lutikizumab hidradenitis suppurativa data and updated Skyrizi and Rinvoq evidence at the 2026 EADV Congress in Vienna on Sept. 30-Oct. 3.